IMAX IMAX CORP

NYSE imax.com


$ 31.30 $ 0.21 (0.68 %)    

Tuesday, 14-Oct-2025 15:59:54 EDT
QQQ $ 598.50 $ -4.01 (-0.67 %)
DIA $ 463.08 $ 2.03 (0.44 %)
SPY $ 662.74 $ -0.81 (-0.12 %)
TLT $ 90.69 $ 0.29 (0.32 %)
GLD $ 382.95 $ 2.70 (0.71 %)
$ 31.3
$ 31.14
$ 30.75 x 8
$ 32.40 x 20
$ 30.74 - $ 31.97
$ 19.91 - $ 34.14
1,293,914
na
1.68B
$ 0.69
$ 51.35
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-24-2025 06-30-2025 10-Q
2 04-23-2025 03-31-2025 10-Q
3 02-19-2025 12-31-2024 10-K
4 10-30-2024 09-30-2024 10-Q
5 07-25-2024 06-30-2024 10-Q
6 04-25-2024 03-31-2024 10-Q
7 02-27-2024 12-31-2023 10-K
8 10-25-2023 09-30-2023 10-Q
9 07-26-2023 06-30-2023 10-Q
10 04-27-2023 03-31-2023 10-Q
11 02-22-2023 12-31-2022 10-K
12 10-31-2022 09-30-2022 10-Q
13 07-28-2022 06-30-2022 10-Q
14 04-28-2022 03-31-2022 10-Q
15 02-23-2022 12-31-2021 10-K
16 10-28-2021 09-30-2021 10-Q
17 07-27-2021 06-30-2021 10-Q
18 04-29-2021 03-31-2021 10-Q
19 03-04-2021 12-31-2020 10-K
20 10-29-2020 09-30-2020 10-Q
21 07-28-2020 06-30-2020 10-Q
22 04-30-2020 03-31-2020 10-Q
23 02-19-2020 12-31-2019 10-K
24 10-31-2019 09-30-2019 10-Q
25 07-30-2019 06-30-2019 10-Q
26 04-26-2019 03-31-2019 10-Q
27 02-26-2019 12-31-2018 10-K
28 10-25-2018 09-30-2018 10-Q
29 07-25-2018 06-30-2018 10-Q
30 05-01-2018 03-31-2018 10-Q
31 02-27-2018 12-31-2017 10-K
32 10-26-2017 09-30-2017 10-Q
33 07-26-2017 06-30-2017 10-Q
34 04-20-2017 03-31-2017 10-Q
35 02-23-2017 12-31-2016 10-K
36 10-20-2016 09-30-2016 10-Q
37 07-20-2016 06-30-2016 10-Q
38 04-21-2016 03-31-2016 10-Q
39 02-24-2016 12-31-2015 10-K
40 10-28-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 roth-capital-maintains-buy-on-imax-raises-price-target-to-40

Roth Capital analyst Eric Handler maintains Imax (NYSE:IMAX) with a Buy and raises the price target from $36 to $40.

 disneys-tron-ares-stumbles-can-zootopia-2-avatar-3-help-end-2025-with-hits

Disney has had multiple box office disappointments in 2025, but could have its biggest hits of the year still to come.

 rosenblatt-maintains-buy-on-imax-raises-price-target-to-42

Rosenblatt analyst Steve Frankel maintains Imax (NYSE:IMAX) with a Buy and raises the price target from $37 to $42.

 jp-morgan-maintains-neutral-on-imax-raises-price-target-to-31

JP Morgan analyst David Karnovsky maintains Imax (NYSE:IMAX) with a Neutral and raises the price target from $28 to $31.

 barrington-research-maintains-outperform-on-imax-maintains-37-price-target

Barrington Research analyst Patrick Sholl maintains Imax (NYSE:IMAX) with a Outperform and maintains $37 price target.

 local-language-hits-are-driving-imax-profits-analysts

IMAX (NYSE: IMAX) expected to grow with strong global releases, higher demand, and new screens. Wedbush raises price forecast t...

 wedbush-maintains-outperform-on-imax-raises-price-target-to-39

Wedbush analyst Alicia Reese maintains Imax (NYSE:IMAX) with a Outperform and raises the price target from $35 to $39.

 barrington-research-maintains-outperform-on-imax-raises-price-target-to-37

Barrington Research analyst Patrick Sholl maintains Imax (NYSE:IMAX) with a Outperform and raises the price target from $32 ...

 did-amc-just-help-the-conjuring-break-records-new-slash-pass-may-be-the-x-factor

Horror films are popular during the fall movie season. AMC is looking to capitalize on this and get more people to theaters in ...

 stranger-things-creators-duffer-brothers-exit-netflix-ink-deal-with-paramount-report

Netflix may lose Duffer brothers to Paramount, ending their successful run with Stranger Things. Stock up 39% YTD, praised for ...

 wells-fargo-maintains-overweight-on-imax-raises-price-target-to-34

Wells Fargo analyst Omar Mejias maintains Imax (NYSE:IMAX) with a Overweight and raises the price target from $30 to $34.

 wedbush-maintains-outperform-on-imax-raises-price-target-to-35

Wedbush analyst Alicia Reese maintains Imax (NYSE:IMAX) with a Outperform and raises the price target from $34 to $35.

 benchmark-maintains-buy-on-imax-raises-price-target-to-32

Benchmark analyst Mike Hickey maintains Imax (NYSE:IMAX) with a Buy and raises the price target from $30 to $32.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION